US2012270749A1PendingUtilityA1
Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
Est. expiryNov 6, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Mathias GebauerMartin MichaelisDanping Ding-PfennigdorffAnke M. SchulteDaniel ZiemekChristiane Metz-Weidmann
G01N 33/6893C12Q 1/6883C12Q 2600/158G01N 2800/2842C12Q 2600/136
25
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a method of identifying a compound involved in pain, the use of C1qb nucleic acid or C1qb protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.
Claims
exact text as granted — not AI-modified1 . A method of identifying a compound involved in pain, the method comprising the steps of:
a) providing a test system comprising C1qb nucleic acid or C1 qb protein or a functionally active variant of a C1qb protein, b) contacting the test system with a test compound, and c) determining the effect of the test compound on the test system, wherein the test compound is identified as a compound involved in pain when a significant effect of the test compound on the test system relative to a control is detected.
2 . (canceled)
3 . The method of claim 1 , wherein the compound involved in pain is a cellular compound which is part of the signal transduction pathway of the C1qb gene and/or the C1qb protein.
4 . The method of claim 3 , wherein the compound involved in pain alters signal transduction upstream or downstream the C1qb protein.
5 . The method of claim 3 , wherein the compound involved in pain alters signal transduction upstream or downstream the C1qb gene.
6 . The method of claim 1 , wherein the compound involved in pain binds to a cellular compound which is part of the signal transduction pathway of the C1qb gene and/or the C1qb protein.
7 . The method of claim 6 , wherein the compound involved in pain inhibits signal transduction upstream or downstream the C1qb gene.
8 . The method of claim 6 , wherein the compound involved in pain inhibits signal transduction upstream or downstream the C1qb protein.
9 . The method of claim 1 , wherein the test system is in a cell.
10 . The method of claim 1 , wherein the method is a high-through-put method.
11 . The method of claim 1 , wherein the pain is neuropathic pain.
12 - 14 . (canceled)
15 . A method of diagnosing algesia, comprising the steps of
a) determining the level expression of the C1qb gene in a subject's sample, and b) identifying the subject as algesic if the level of expression of the C1qb gene is increased in the subject's sample relative to a control sample.
16 . The method of claim 5 , wherein the compound alters expression of the C1qb gene.
17 . The method of claim 6 , wherein the compound involved in pain binds to the C1qb nucleic acid.
18 . The method of claim 7 , wherein the compound involved in pain inhibits expression of the C1qb gene.
19 . The method of claim 8 , wherein the compound involved in pain binds to the C1qb protein.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.